or Try an Advanced Search...

    Technical Analysis for ABVC - ABVC Biopharma, Inc.

    Grade Last Price % Change Price Change
    F 1.09 0.93% 0.01
    ABVC closed unchanged on Wednesday, May 15, 2024, on 23 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Flat
    Historical ABVC trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.93%
    Oversold Stochastic Weakness 0.93%
    Narrow Range Bar Range Contraction 0.93%
    Earnings Movers Other 0.93%
    Wide Bands Range Expansion 0.93%
    Oversold Stochastic Weakness 0.93%
    Earnings Movers Other 1.87%
    Wide Bands Range Expansion 1.87%
    Oversold Stochastic Weakness 1.87%
    NR7 Range Contraction 2.83%
    Older End-of-Day Signals for ABVC ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support about 2 hours ago
    Rose Above 10 DMA about 2 hours ago
    Up 1% about 2 hours ago
    Rose Above 10 DMA about 23 hours ago
    Up 3% about 23 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ABVC Chart by TradingView
    Basic chart:

    Profile

    ABVC Biopharma, Inc. Description

    American BriVision (Holding) Corporation, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, a combination therapy for triple negative breast cancer; ABV-1504 for major depressive disorders; ABV-1505 for attention deficit hyperactivity disorder; ABV-1703 for the treatment of pancreatic cancer; ABV-1702 to treat myelodysplastic syndromes; ABV-1601 for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company was incorporated in 2015 and is based in Fremont, California. American BriVision (Holding) Corporation is a subsidiary of YuanGene Corporation.

    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Cancer Pancreatic Cancer Depression Major Depressive Disorder Myelodysplastic Syndrome Attention Deficit Hyperactivity Disorder Treatment Of Pancreatic Cancer Triple Negative Breast Cancer

    Is ABVC a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 15 Promising Combination Therapy for Triple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M
    May 9 Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
    Apr 18 AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share
    Apr 17 ABVC BioPharma executes licensing agreement with OncoX
    Apr 17 ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M
    Apr 10 ABVC Biopharma stock climbs on deal for its oncology/hematology products
    Apr 10 ABVC BioPharma Executes a Global Licensing Term Sheet for Oncology/Hematology Products, Expecting Licensing Income of $55M and Royalties of up to $50M
    Mar 26 Why ABVC BioPharma Stock Is Up Today
    Mar 26 ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M
    Mar 21 AiBtl BioPharma Inc. Completes $7.6M Land Deal: Exchanging Stock for Real Estate, Demonstrating the Value of ABVC's 23M AiBtl Share Ownership as Hundred Million Dollars
    See more ABVC news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 8.1
    52 Week Low 0.697
    Average Volume 1,398,011
    200-Day Moving Average 1.31
    50-Day Moving Average 1.19
    20-Day Moving Average 1.18
    10-Day Moving Average 1.09
    Average True Range 0.11
    RSI (14) 43.82
    ADX 19.28
    +DI 30.65
    -DI 19.18
    Chandelier Exit (Long, 3 ATRs) 1.39
    Chandelier Exit (Short, 3 ATRs) 1.28
    Upper Bollinger Bands 1.52
    Lower Bollinger Band 0.84
    Percent B (%b) 0.35
    BandWidth 57.11
    MACD Line -0.04
    MACD Signal Line -0.02
    MACD Histogram -0.014
    Fundamentals Value
    Market Cap 8.55 Million
    Num Shares 7.91 Million
    EPS -3.57
    Price-to-Earnings (P/E) Ratio -0.30
    Price-to-Sales 14.34
    Price-to-Book 1.13
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 1.17
    Resistance 3 (R3) 1.17 1.15 1.16
    Resistance 2 (R2) 1.15 1.12 1.15 1.15
    Resistance 1 (R1) 1.11 1.11 1.13 1.11 1.14
    Pivot Point 1.09 1.09 1.10 1.09 1.09
    Support 1 (S1) 1.05 1.06 1.07 1.05 1.02
    Support 2 (S2) 1.03 1.05 1.03 1.01
    Support 3 (S3) 0.99 1.03 1.01
    Support 4 (S4) 0.99